AgeX Therapeutics, Inc. (AGE) Income Statement Analysis

See more : Tande Co., Ltd. (600665.SS) Income Statement Analysis – Financial Results

Complete financial analysis of AgeX Therapeutics, Inc. (AGE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AgeX Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

AgeX Therapeutics, Inc. (AGE)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.agexinc.com

About AgeX Therapeutics, Inc.

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.

Metric	2023	2022	2021	2020	2019	2018	2017
Revenue	142.00K	34.00K	144.00K	1.87M	1.73M	1.40M	1.40M
Cost of Revenue	171.00K	13.00K	19.00K	158.00K	244.00K	364.00K	168.00K
Gross Profit	-29.00K	21.00K	125.00K	1.71M	1.48M	1.03M	1.24M
Gross Profit Ratio	-20.42%	61.76%	86.81%	91.54%	85.88%	73.93%	88.03%
Research & Development	603.00K	1.03M	1.46M	4.98M	5.90M	6.63M	5.78M
General & Administrative	9.33M	5.97M	6.71M	7.40M	8.14M	5.65M	3.87M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	9.33M	5.97M	6.71M	7.40M	8.14M	5.65M	3.87M
Other Expenses	11.00K	13.00K	448.00K	44.00K	294.00K	183.00K	38.00K
Operating Expenses	9.93M	7.00M	8.16M	12.38M	14.04M	12.28M	9.65M
Cost & Expenses	10.10M	7.01M	8.18M	12.54M	14.29M	12.64M	9.82M
Interest Income	0.00	3.34M	1.10M	404.00K	29.00K	0.00	0.00
Interest Expense	4.90M	3.34M	1.10M	0.00	0.00	116.00K	0.00
Depreciation & Amortization	131.00K	145.00K	579.00K	1.68M	951.00K	535.00K	682.00K
EBITDA	-9.83M	-6.98M	-7.93M	-9.15M	-11.61M	-10.71M	-9.49M
EBITDA Ratio	-6,921.83%	-20,088.24%	-5,180.56%	-481.21%	-671.76%	-767.19%	-675.85%
Operating Income	-9.96M	-6.98M	-8.04M	-10.67M	-12.56M	-11.25M	-6.66M
Operating Income Ratio	-7,014.08%	-20,514.71%	-5,582.64%	-571.25%	-726.79%	-805.52%	-474.57%
Total Other Income/Expenses	-4.85M	-3.55M	-649.00K	272.00K	323.00K	3.51M	1.78M
Income Before Tax	-14.81M	-10.52M	-8.58M	-11.13M	-12.24M	-7.73M	-6.64M
Income Before Tax Ratio	-10,430.28%	-30,947.06%	-5,959.72%	-595.61%	-708.10%	-553.80%	-472.72%
Income Tax Expense	-8.00K	152.00K	1.64M	-150.00K	148.00K	3.51M	-1.80M
Net Income	-14.80M	-10.67M	-10.22M	-10.98M	-12.38M	-7.50M	-6.58M
Net Income Ratio	-10,424.65%	-31,394.12%	-7,097.22%	-587.58%	-716.67%	-537.39%	-468.66%
EPS	-13.72	-9.89	-9.49	-10.25	-11.69	-7.56	-6.46
EPS Diluted	-13.72	-9.89	-9.49	-10.25	-11.69	-7.56	-6.46
Weighted Avg Shares Out	1.08M	1.08M	1.08M	1.07M	1.06M	992.72K	1.02M
Weighted Avg Shares Out (Dil)	1.08M	1.08M	1.08M	1.07M	1.06M	992.72K	1.02M